论文部分内容阅读
目的:观察联合应用巴曲酶及尤瑞克林治疗急性脑梗死的临床疗效、NIHSS评分和日常生活能力评分巴氏指数的情况,并对PLT、PT、APTT的影响。方法:选择50例急性脑梗死患者作为观察对象,随机分为对照组(男13例,女12例)和观察组(男14例,女11例),对照组给予急性脑梗死常规治疗2周,观察组在其基础上给予巴曲酶+尤瑞克林连续治疗5天。分析2组治疗前后NIHSS、巴氏指数、PLT、PT及APTT的影响。结果:与对照组相比,观察组NIHSS、巴氏指数及治疗有效率有显著改善,差异有统计学意义(P<0.05);2组治疗前后比较及治疗后对比比较,PLT、PT及APTT变化不大,差异均无统计学意义(P>0.05)。结论:巴曲酶联合尤瑞克林治疗急性脑梗死临床疗效显著,且安全可靠,值得在临床上推广。
OBJECTIVE: To observe the clinical efficacy, the NIHSS score and the Papanicum Index score of daily living ability in patients with acute cerebral infarction combined with batroxobin and uracil and the effects on the PLT, PT and APTT. Methods: Fifty patients with acute cerebral infarction were randomly divided into control group (13 males and 12 females) and observation group (14 males and 11 females). The control group was given conventional treatment of acute cerebral infarction for 2 weeks , The observation group on the basis of batroxobin + uricin sustained treatment for 5 days. The effects of NIHSS, Papanicum index, PLT, PT and APTT before and after treatment were analyzed. Results: Compared with the control group, the NIHSS, the Papanicum index and the treatment effective rate in the observation group were significantly improved (P <0.05); compared before and after treatment and post-treatment comparison, PLT, PT and APTT Little change, the difference was not statistically significant (P> 0.05). Conclusion: The clinical efficacy of batroxobin combined with nociceptin in the treatment of acute cerebral infarction is significant, safe and reliable, which is worth to be popularized clinically.